The Efficacy of Citalopram Treatment in Acute Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 642 participants.

Also called NCT01937182

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 642 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01937182
Other papers using this trial's data
  • Impact of prestroke physical activity and citalopram treatment on poststroke depressive symptoms: a secondary analysis of data from the TALOS randomised controlled trial in Denmark BMJ open, 2023-03-30 DOI, PubMed 36997260, PMC10069592 In the PMC Open Access subset under CC BY-NC.
  • Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS) Stroke, 2018-11 DOI, PubMed 30355209

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01937182. Randomized; quadruple masking; primary purpose treatment. Start 2013-09 (actual); primary completion 2016-12-19 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Efficacy of Citalopram Treatment in Acute Stroke
Acronym
TALOS
Condition
Stroke, Ischemic
Intervention (Drug)
Citalopram
Intervention (Drug)
Placebo
Lead sponsor
University of Aarhus (class: other)
Collaborator
Danish Council for Independent Research (class: other)
Collaborator
The Danish Regions Medicine Foundation (class: not stated)

Record details

Record id
cardio:ct-nct01937182
Content hash
1ac8e829c6e562349f66dceaf83bcea880ca632d399ffb188b399d333330f549